Inhaled adrenergic bronchodilators: Historical development and clinical application

Respiratory Care

Volumn 45, Issue 7, 2000, Pages 854-863

  Rau, Joseph L ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Adrenergic; Aerosol; Asthma; Beta agonist; Bronchodilator; Inhaled; Isomer

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; HERBACEOUS AGENT;

ARTICLE; ASTHMA; DRUG SCREENING; HISTORY; HUMAN; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG EVALUATION; DRUGS, CHINESE HERBAL; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS;

EID: 0034221926     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Chen KK, Schmidt CF. The action of ephedrine, the active principle of the Chinese drug Ma Huang. J Pharmacol Exp Ther 1925;24:339.
2. Solis-Cohen S. The use of adrenal substance in the treatment of asthma. JAMA 1900;34:1164.
3. Aranson R, Ran JL. The evolution of beta-agonists. Respir Care Clin N Am 1999;5(4):479-519.
4. Hartung WH. Epinephrinc and related compounds: influence of structure on physiologic activity. Chem Rev 1931;9:389.
5. Wilson NL. Clinical notes on adrenalin. Laryngoscope 1901;Jul:63-66.
6. Bullowa JGM, Kaplan DM. On the hyperdermatic use of adrenalin chloride in the treatment of asthmatic attacks. Med News 1903;83: 787.
7. Kahn R. Zur physiologie der trachea. Arch Physiol 1907;398-126.
8. Barger G, Dale HH. Chemical structure and sympathomimetic action of amines. J Physiol 1910;41:19.
9. Leifer KN, Wittig HJ. The beta-2 sympathomimetic aerosols in the treatment of asthma. Ann Allergy 1975;35(2):69-80.
10. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600.
11. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature (London) 1967;214:597-598.
12. Fraser CM, Venter JC. Beta-adrenergic receptors: Relationship of primary structure, receptor function, and regulation. Am Rev Respir Dis 1990;141(2 Pt 2):S22-S30.
13. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998; 158(5 Pt 3):S146-S153.
14. 2-adrenergic receptor-agonist interaction. In: Leff AR, editor. Pulmonary and critical care pharmacology and therapeutics. New York: McGraw-Hill; 1996: 451-462.
15. Bakale RP, Wald SA, Butler HT, Gao Y, Hong Y, Nie X, Zepp CM. Albuterol: a pharmaceutical chemistry review of R-, S-, and RS-albuterol. Clin Rev Allergy lmmunol 1996;14(1):7-35.
16. Brittain RT, Jack D, Ritchie AC. Recent β-adrenoceptor stimulants. Adv Drug Res 1970;5:197-253.
17. Dickison AE. Child with upper airway obstruction: Part III. Respir Management 1990;20:66.
18. Rau JL. Respiratory therapy pharmacology (1/e). Chicago: Year Book; 1978.
19. Richards DM, Brogden RN. Pirbuterol: a preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease (review). Drugs 1985;30(1):6-21.
20. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapuetic potential in reversible obstructive airways disease. Drug Eval 1991;42(5):895.
21. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir Dis 1991;4(10):1178-1184.
22. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, Rollins TE, Rubin PD. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102(6 Pt 1):943-952.
23. McFadden ER Jr. Clinical use of β-adrenergic agonists. J Allergy Clin Immunol 1985;76(2 Pt 2):352-356.
24. Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol at high and low doses, in the treatment of severe acute asthma in adults. Chest 1996;110(1):42-47.
25. Jenne JW. Physiologic actions of beta-adrenergic agonists. In: Leff AR, editor. Pulmonary and critical care pharmacology and therapeutics. New York: McGraw-Hill; 1996: 473-482.
26. Hayes MJ, Qing F, Rhodes CG, Rahman SU, Ind PW, Sriskandan S, et al. In vivo quantification of human pulmonary β-adrenoceptors: effect of β-agonist therapy. Am J Respir Crit Care Med 1996;154(5): 1277-1283.
27. Page CP. Beta agonists and the asthma paradox. J Asthma 1993; 30(3):155-164.
28. Speizer FE, Djoll R, Heaf P, Strang LB. Investigation into use of drugs preceding death from asthma. Br Med J 1968;(5588):339-343.
29. Stolley P. Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972;105(6): 883-890.
30. 2-agonist controversy revisited. Ann Allergy Asthma Immunol 1995;75(2):173-176.
31. Granger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1987: a further case-control study. Thorax 1991;46(2):105-111.
32. Haas JF, Staudinger HW, Schuijt C. Asthma deaths in New Zealand. Br Med J 1992;304(6482):1634.
33. Crane J, Buragess C, Pearce N, Beasley R, Jackson R. Asthma deaths in New Zealand. Br Med J 1992;304(6837):1307.
34. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326(8):501-506.
35. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336(8728):1391-1396.
36. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled β-agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48(2):134-138.
37. 2-agonists in asthma. N Engl J Med 1992; 327(17):1204-1208.
38. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342(8875):833-837.
39. Templeton AGB, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Therapeutics 1998;11(1):1-6.
40. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phosphoplipase C-dependent mechanism in airway smooth muscle. Molec Pharmacol 1998;53(3):347-354.
41. Volcheck GW, Gleich GJ, Kita H. Pro-and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol 1998;101:S35.
42. Boulton DW, Fawcett JP. Pharmcokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther 1997;62(2):138-144.
43. Johansson F, Rydberg I, Aberg G, Andersson RG. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996;14(1):57-64.
44. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160(4):1136-1141.
45. 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997; 52(10):849-852.
46. Schmekel B, Rydberg I, Norlander B, Sjöswärd KN, Ahlner J, Adnersson RG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 1999;13(6):1230-1235.
47. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. Bethesda, 1997; National Institutes of Health, NHLBI, NIH Publication No. 97-4051. Available at: www.nhlbi.nih.gov/guidelines/ asthma/asthgdln.htm. Accessed June 6, 2000.